Samsung Bioepis and Organon Expand Collaboration Agreement
Samsung Bioepis and Organon, a global healthcare company with expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to Pyzchiva, Samsung Bioepis's biosimilar referencing Stelara - ustekinumab -. Pyzchiva is indicated for the treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn's disease who have had an inadequate response to either immunomodulators or one or more tumour necrosis factor-alpha antagonists, or have had an inadequate response, intolerance or demonstrated dependence on corticosteroids, moderately to severely active ulcerative colitis who have had an inadequate response to either conventional therapy or a biologic or have medical contraindications to such therapies. Organon will obtain exclusive commercial rights to the product in Canada while Samsung Bioepis will maintain full development, manufacturing, and regulatory responsibilities. This agreement expands the biosimilar portfolio under Organon and Samsung Bioepis's collaboration in Canada from five to six complementary products. An estimated 1 in 140 Canadians lives with Crohn's or colitis, the two main forms of inflammatory bowel disease. Pyzchiva is expected to be launched in the market in 2026.
